Monitoring and management of heparin-induced thrombocytopenia.
Low molecular weight heparins have been used to reduce thromboembolic risk for at least 20 years, but their use is not without risk. This article considers the incidence, monitoring, treatment and lack of insight about heparin-induced thrombocytopenia - a potentially fatal complication of low molecular weight heparin use.
Rogers
Ba
B
Trauma and Orthopaedics, St George's Hospital, London, UK.
Little
Nj
Nj
Jones
C
C
D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use; D004797:Enzyme-Linked Immunosorbent Assay; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D017410:Practice Guidelines as Topic; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000175:diagnosis; D013923:Thromboembolism / Q000517:prevention & control*
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight